Exact Sciences' Earnings Hammer Short-Sellers (Again)
Americans have historically done poorly when it comes to sticking to recommended guidelines for colon cancer screening, but a new test launched by Exact Sciences (NASDAQ: EXAS) may be changing that -- and frustrating short-sellers in the process.
Bears have been lining up against Exact Sciences since Cologuard's launch, arguing that the test isn't nearly as useful as a colonoscopy and that doctors and patients will shun it. So far, that hasn't been the case, and as a result, short-sellers have been forced to cover their position in Exact Sciences, pushing shares higher.
Image source: Getty Images.
Source: Fool.com
Exact Sciences Stock
€47.83
-2.180%
With 13 Buy predictions and not the single Sell prediction the community is currently very high on Exact Sciences.
With a target price of 82 € there is a hugely positive potential of 71.46% for Exact Sciences compared to the current price of 47.83 €.
